# Neoadjuvant SBRT With Concomitant Capecitabine in Resectable Pancreatic Cancer

> **NCT01918644** · PHASE1 · COMPLETED · sponsor: **University of Wisconsin, Madison** · enrollment: 21 (actual)

## Conditions studied

- Stage IA Pancreatic Cancer
- Stage IB Pancreatic Cancer
- Stage IIA Pancreatic Cancer
- Stage IIB Pancreatic Cancer

## Interventions

- **RADIATION:** stereotactic body radiation therapy
- **DRUG:** capecitabine
- **PROCEDURE:** therapeutic conventional surgery
- **PROCEDURE:** magnetic resonance imaging
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01918644
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-08
- **Primary completion:** 2019-12-04
- **Final completion:** 2022-04-26
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2022-06-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01918644

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01918644, "Neoadjuvant SBRT With Concomitant Capecitabine in Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01918644. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*